Hair Loss Therapy

Hair loss at ALPHALABS is treated as a medical condition with a clear physiological mechanism, not a cosmetic inconvenience. The clinic's programme focuses specifically on androgenic alopecia — the most common form of male hair loss — which is driven by the conversion of testosterone to dihydrotestosterone (DHT) in hair follicles. DHT binds to androgen receptors in the scalp, progressively miniaturising follicles until they can no longer produce visible…

The programme begins with a physician consultation covering the client's hair loss history, family pattern, current rate of shedding, scalp condition and any previous treatments tried. A scalp and hair assessment determines the distribution and severity of miniaturisation (typically graded using the Norwood–Hamilton scale for men), which guides treatment selection and sets a baseline for progress measurement.

Treatment follows a two-phase structure. Phase one uses a DHT-inhibiting agent to reduce circulating scalp DHT levels, thereby halting the continued miniaturisation of susceptible follicles. Phase two introduces a follicle-stimulating component to encourage regrowth in recently dormant follicles. The physician chooses between two delivery forms: a topical solution (applied directly to the scalp, lower systemic exposure, marginally less potent) or oral…